For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Rutgers Health researchers will enroll patients with primary or secondary progressive multiple sclerosis (p-MS) patients to see if an engineered immune cell therapy can halt the progression of the ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

Genentech’s newly approved multiple sclerosis (MS) injection takes about 10 minutes to administer, dramatically reducing the ...

The Food and Drug Administration (FDA) has approved Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing form of multiple sclerosis (MS), to include clinical isolated ...

A groundbreaking study has unveiled a critical issue of therapeutic inertia in treating women with multiple sclerosis (MS ... of initiating or intensifying treatment for a medical condition ...

The research, presented today at ECTRIMS 2024, is the result of efforts by the Alliance for Research in Hispanic MS (ARHMS) Consortium and is the first large-scale study to identify ancestry-specific ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...